ClinicalTrials.gg
RecruitingNCT06832007Updated Oct 9, 2026

The Effect of Light Intervention on Recovery in Individuals With Opioid Use Disorder (OUD)

An interventional study of AYO light glasses (experimental) and AYO light glasses (comparator) in Opioid Use Disorder, Sleep and Circadian Rhythms, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham — 5 open to participants now, 5 under way, none of them phase 3. Opioid-Related Disorders · University of Alabama at Birmingham.

Started
2025
with 2 others
No phase
4 of 10
3 open now
Registered
8th of 10
by date

Among the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 8th registered.

Opioid-Related Disorders

1,475 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

5 of the 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Opioid-Related Disorders by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

Opioid use disorder (OUD) is a chronic relapsing disorder and is well-known for its high-risk rate of overdoses and death. In OUD, sleep and circadian disruptions are highly prevalent, interfere with opioid maintenance treatment outcomes and increase the risk of relapse. So far, commonly used pharmacological sleep treatments fail to improve sleep or decrease illicit drug use in OUD. Thus, there is an urgent need to fill this research gap.

Previous work showed that OUD patients who were receiving opioid agonist treatment (MOUD+) exhibited greater irregularity of sleep-wake cycle. In OUD patients, sleep-wake irregularity was associated with years of heroin use and low light exposure. Bright light therapy (BLT) is a very promising circadian/sleep intervention for several sleep, psychiatric and neurological disorders. BLT improved circadian, sleep outcomes and negative mood. In a pilot study, BLT improved objective and subjective sleep in patients with alcohol use disorder. Here investigators proposed an intervention study for MOUD+ patients to determine effects of BLT as an adjunct treatment on sleep and circadian outcomes including endogenous circadian rhythm, rest-activity rhythm and sleep neurophysiology (Primary objectives); and to determine effects of BLT on brain function and on clinical outcomes including negative affect, craving and illicit drug use and whether changes in sleep and circadian rhythm mediate the BLT effect on brain recovery and clinical outcomes (Secondary objectives).

Fifty MOUD+ will be assigned either to bright light or to dim light group for 2 weeks. The groups will be matched for age, sex, race and OUD medication (Methadone vs Buprenorphine). The study will run throughout the year such that it occurs during all seasons. Light exposure will be measured with light sensor for additional control. All MOUD+ participants will have a daily 30-min light exposure (bright or dim blue light) in the morning after their habitual wake-up time and will be asked to avoid evening light before bed. Dim light melatonin onset, accelerometer, sleep EEG and questionnaires will be used to measure objective and subjective sleep and circadian outcomes. For brain function, cue-reactivity task will be used to assess brain activation during drug craving. Resting state functional connectivity and brain state dynamics will be assessed by rsfMRI. Mood, opiate craving and illicit drug use will be assessed. All measures will be repeated before and after the treatment. Investigators expect that BLT would normalize sleep and circadian outcomes, attenuate impairments in brain functions and result in better clinical outcomes. If successful, light therapy will provide add-on benefits to opioid agonist therapy and facilitate OUD recovery process.

03

Conditions studied

  • Opioid Use Disorder
  • Sleep
  • Circadian Rhythms
  • fMRI Research

Keywords

  • opioid use disorder
  • sleep
  • circadian rhythms
  • fMRI research
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All Participants
  • Between 18 and 60 years old
  • Fluent in English
  • Able to provide written

OUD

  • diagnosis of an OUD.
  • ≥12 months of lifetime opioid use
  • Positive on urine drug screen for buprenorphine or methadone
  • Receiving opioid agonist therapy for OUD (e.g., methadone or buprenorphine) with a stable dose for the past month. Must have been stabilized on OMT medication, since the increasing of doses during induction phase might interfere with outcomes and unstable patients might experience strong withdrawal symptoms in the morning which makes them unsuitable for a home-based BLT.
  • Other substance use was not exclusionary, but opioids were identified as primary.

Exclusion criteria

Exclusion Criteria:

All Participants

  • Head trauma with loss of consciousness for more than 30 minutes as determined by medical history.
  • history of seizures/epilepsy.
  • Pregnant and/or currently breast-feeding.
  • Presence of ferromagnetic objects in the body that are for MRI or fear of enclosed spaces.
  • Eye disease including disease of the anterior and posterior segment of the eye, cataracts, retinopathy, glaucoma, amblyopia, scotoma, color or night blindness, corneal pathologies, macular degeneration, or retinitis pigmentosa reported by history or identified by eye exam
  • History of eye surgery
  • Chronic migraine triggered by bright light
  • worked night shift or traveled across>2 time zones in the past month

OUD

  • diagnosis of substance use disorder other than for opioids that was deemed to be primary
  • lifetime diagnosis of schizophrenia, bipolar disorder, or suicidality.
  • History of light treatment
  • Unstable dose of psychiatric medication (hypnotics, sleep aids, and antidepressants must be stable for 30 days before and during the study)

HC

  • Current or past or DSM-5 diagnosis of a psychiatric disorder including substance use disorder (except for nicotine/caffeine).
  • Current DSM-5 sleep-wake disorders including insomnia disorder
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Experimental light

    MOUD participants

    Device: AYO light glasses (experimental)

  • Active comparator
    Comparison light

    MOUD participants

    Device: AYO light glasses (comparator)

  • No intervention
    Healthy control

Interventions

  • DeviceAYO light glasses (experimental)

    OUD patients are asked to wear AYO light therapy glasses (wavelength 470nm ± 2nm, irradiance 250 μW/cm2 or approx.1500 m-EDI) daily for 30 min after habitual wake-up times for two weeks.

  • DeviceAYO light glasses (comparator)

    The comparison group will wear the same AYO glasses but with lower intensity (1% light intensity) compared to the experimental group. This group will also self-administer 30 min of light from commercially available light glasses each morning for two weeks

06

What researchers measure

Primary outcomes

  1. Dim light melatonin onset (DLMO)

    DLMO is assessed for endogenous circadian phase.Participants will be asked to remain awake in dim light \< 5 lux. Salivary melatonin sample will be collected hourly and start 5h before habitual bedtime. Melatonin concentration will be later radioimmunoassayed. DLMO will be calculated as the time when melatonin concentration exceeds and remains above 4 pg/mL.

    Time frame: the day directly before and after the intervention

  2. melatonin metabolites level

    Participants will be asked to collect their first morning urine void (overnight urine) upon waking. Urinary metabolite of melatonin 6-sulphatoxymelatonin (aMT6s) will be quantified and normalized to urinary creatinine concentrations to account for variations in urine concentration.

    Time frame: the day directly before and after the intervention

  3. Sleep-wake regularity

    To record rest-activity/sleep-wake patterns, participants are asked to wear a triaxial accelerometer placed on the non-dominant wrist continuously throughout the study.

    Time frame: From the enrollment to the end of the treatment at 24 days

  4. Total sleep duration

    total sleep duration (hours) will be measured by sleep EEG. Participants will be asked to wear a wireless sleep monitor device during sleep in their home environment.

    Time frame: From the enrollment to the end of the treatment at 24 days; 2-3 nights per week

  5. N3 sleep

    N3 sleep (hours) will be measured by sleep EEG. Participants will be asked to wear a wireless sleep monitor device during sleep in their home environment.

    Time frame: From the enrollment to the end of the treatment at 24 days; 2-3 nights per week

  6. REM sleep

    REM sleep (hours) will be measured by sleep EEG. Participants will be asked to wear a wireless sleep monitor device during sleep in their home environment.

    Time frame: From the enrollment to the end of the treatment at 24 days; 2-3 nights per week

  7. sleep spindle

    Amount of sleep spindle will be measured by sleep EEG. Participants will be asked to wear a wireless sleep monitor device during sleep in their home environment.

    Time frame: From the enrollment to the end of the treatment at 24 days; 2-3 nights per week

Secondary outcomes

  1. brain signiture of craving measured by cue reactivity task

    Participants will passively view neutral, food and opioid related pictures. Brain activity during the picture viewing will be captured.

    Time frame: the day prior to the intervention and the day after the intervention

  2. brain functions during resting state

    resting state fMRI data will be collected over an 8-min period of time. Brain functional connectivity and brain state transitions will be calculated

    Time frame: the day before and after light intervention

  3. Ecological momentary assessment (EMA)

    self-reported mood, opioid craving, withdrawal symptoms and illicit drug use will be captured by EMA surveys. The MetricWire platform will be utilized for EMA surveys. Sleep-related questions will be prompted within 1 hour of the participant's habitual wake-up time. For the OUD group, additional questions will include prior day's illicit drug use and the usage of buprenorphine and methadone (time and dose). Light therapy-related questions, including onset and offset times, adverse effects, and changes in positive and negative mood after the daily therapy session, will be collected before 1 pm. Questions on mood, craving, and pain severity will be delivered at six semi-random timepoints each day during the participant's waking hours.

    Time frame: From the enrollment to the end of the treatment at 24 days

Other outcomes

  1. post-illumination pupil response

    Upon arrival, the non-dominate eye will be dilated with Tropicamide 0.5% and Phenylephrine 2.5%. Participants are then seated in a dimly lit room (\< 5 lux, background light) for 30 min to dark adapt and to ensure complete pupil dilation prior to the study. The PIPR is measured in eight, 71-second test periods in which the stimulus, either Blue (470 nm) or Red (623 nm), is presented to the dilated eye while the pupil response of the un-dilated eye is measured (consensual pupil response). During a test period, after an initial 20-second fixation period, the stimulus is presented for 1 second followed by a 50-second recording period. The red stimulus primarily serves as a control for any nonspecific influences on the PIPR.

    Time frame: study visit prior to the treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2028, 36 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 36 months is above that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 18, 2025
StartActual
Sep 6, 2025
Primary completionEst.
Sep 16, 2028
CompletionEst.
Sep 16, 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06832007
Responsible party
Rui Zhang (Assistant Professor, University of Alabama at Birmingham) — Principal investigator
First posted
Feb 18, 2025
Start date
Sep 6, 2025
Primary completion
Sep 16, 2028 (estimated)
Completion
Sep 16, 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Rui Zhang, PhD
Contact
rzhang5@uab.edu
2059966170

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion